Kymera Posts $2.87M Q4 Revenue Miss While Advancing First IRF5 Therapy
Kymera reported Q4 revenue of $2.87M and EPS of -$0.97, missing estimates of $17.3M and -$0.79, while advancing its pipeline with the first-in-human IRF5-directed therapy and Phase 1b data showing oral STAT6 degrader KT-621 matched dupilumab efficacy. The company holds $1.62B cash runway into 2029.
1. Q4 Financial Results
Kymera reported Q4 revenue of $2.87M and EPS of -$0.97, missing analyst estimates of $17.3M revenue and -$0.79 EPS. The shortfall reflects the company’s focus on clinical development rather than product sales.
2. Pipeline Advancements
Kymera dosed the first IRF5-directed therapy (KT-579) in a Phase 1 healthy volunteer trial and unveiled Phase 1b data showing its oral STAT6 degrader KT-621 matched or exceeded published dupilumab efficacy at four weeks in atopic dermatitis patients.
3. Cash Position and Outlook
A $692M equity raise completed in December boosted cash to $1.62B, extending runway into 2029. Two Phase 2b trials for KT-621—BROADEN2 in atopic dermatitis and BREADTH in asthma—have top-line readouts expected mid-2027 and late 2027, respectively.